Provided by Tiger Trade Technology Pte. Ltd.

Phio Pharmaceuticals

1.14
+0.07006.54%
Post-market: 1.10-0.0399-3.50%19:28 EST
Volume:550.35K
Turnover:618.91K
Market Cap:12.27M
PE:-0.53
High:1.16
Open:1.06
Low:1.06
Close:1.07
52wk High:4.19
52wk Low:0.8127
Shares:10.76M
Float Shares:10.71M
Volume Ratio:0.89
T/O Rate:5.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1500
EPS(LYR):-9.0798
ROE:-107.58%
ROA:-60.16%
PB:1.25
PE(LYR):-0.13

Loading ...

Phio Pharmaceuticals Corp - No Dose-Limiting Toxicities in Ph-762 Trial - SEC Filing

THOMSON REUTERS
·
Dec 23, 2025

Phio Pharmaceuticals Corp - Ph-762 Has Been Well Tolerated in All Enrolled Patients in Each Escalating Dose Cohort

THOMSON REUTERS
·
Dec 23, 2025

Phio Pharmaceuticals Corp - Initiatives Continuing to Advance Delivery of Commercially Viable Drug Product in 2026

THOMSON REUTERS
·
Dec 23, 2025

Phio Pharmaceuticals Announces FDA Acceptance of Nonclinical Study Design for PH-762

Reuters
·
Dec 23, 2025

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial

TIPRANKS
·
Nov 26, 2025

Phio Pharmaceuticals Completes Phase 1b Enrollment for PH-762 Skin Cancer Trial

Reuters
·
Nov 26, 2025

Phio Pharmaceuticals CEO Robert J. Bitterman Reports Acquisition of Common Shares

Reuters
·
Nov 25, 2025

BRIEF-Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing

Reuters
·
Nov 21, 2025

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

TIPRANKS
·
Nov 21, 2025

Phio Pharmaceuticals Corp Files for Offering of up to 11.8 Mln Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Nov 21, 2025

Phio Pharmaceuticals CEO Robert J. Bitterman Acquires Common Shares

Reuters
·
Nov 20, 2025

Phio Pharmaceuticals to Present INTASYL siRNA Technology at Advanced Therapies USA Congress

Reuters
·
Nov 17, 2025

Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate

Benzinga
·
Nov 14, 2025

Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Trial Results and Extends Cash Runway Into 2027

Reuters
·
Nov 14, 2025

Phio Pharmaceuticals Unveils Phase 1b Clinical Results for INTASYL PH-762 in Skin Cancer Trial

Reuters
·
Nov 07, 2025

Phio Pharmaceuticals Exercises Warrants for $13.4 Million

TIPRANKS
·
Nov 07, 2025

Phio Pharmaceuticals Shares Rise After Positive Trial Results for PH-762

Dow Jones
·
Nov 04, 2025

Why Is Phio Pharmaceuticals Stock Up 75% Today?

TIPRANKS
·
Nov 03, 2025

Phio Pharmaceuticals Corp - Safety Committee Issues Favorable Review at Maximum Dose of Intasyl Ph-762- SEC Filing

THOMSON REUTERS
·
Nov 03, 2025

Phio Pharmaceuticals Appoints New Lead Independent Director

TIPRANKS
·
Oct 31, 2025